Uncertain Future For Orphazyme After EMA Snub
Agency Set To Reject Arimoclomol For Niemann-Picks Type C
The EMA's medicines evaluation committee has told Orphazyme it will not approve the rare disease drug arimoclomol when it meets at the end of March, prompting the Danish firm to assess its strategic options.
